dobutamine injection, USP 250 mg/20 ml VIAL Dosage and Administration Patient information

Medication Guide

Health Professional Information

Prescribing Information

Health Professional Information

Dosage and Administration

DOSAGE AND ADMINISTRATION

Note − Do not add Dobutamine Injection, USP to 5% Sodium Bicarbonate Injection or to any other strongly alkaline solution. Because of potential physical incompatibilities, it is recommended that dobutamine hydrochloride not be mixed with other drugs in the same solution. Dobutamine hydrochloride should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol.

Preparation and Stability − At the time of administration, Dobutamine Injection, USP must be further diluted in an intravenous container to at least a 50 mL solution using one of the following intravenous solutions as a diluent: 5% Dextrose Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; 10% Dextrose Injection, USP; Isolyte® M with 5% Dextrose Injection; Lactated Ringer's Injection; 5% Dextrose in Lactated Ringer's Injection; Normosol®-M in D5-W; 20% Osmitrol® in Water for Injection; 0.9% Sodium Chloride Injection, USP; or Sodium Lactate Injection, USP. Intravenous solutions should be used within 24 hours.

Recommended Dosage − The rate of infusion needed to increase cardiac output usually ranged from 2.5 to 15 mcg/kg/min (see Table 1). On rare occasions, infusion rates up to 40 mcg/kg/min have been required to obtain the desired effect.

Table 1 Dobutamine Infusion Rate (mL/kg/min) for Concentrations of 250, 500, and 1,000 mcg/mL
Drug Delivery Rate	Infusion Delivery Rate
Drug Delivery Rate	250 mcg/mL*	500 mcg/mL†	1,000 mcg/mL‡
(mcg/kg/min)	(mL/kg/min)	(mL/kg/min)	(mL/kg/min)
2.5	0.01	0.005	0.0025
5	0.02	0.01	0.005
7.5	0.03	0.015	0.0075
10	0.04	0.02	0.01
12.5	0.05	0.025	0.0125
15	0.06	0.03	0.015
* 250 mcg/mL of diluent † 500 mcg/mL or 250 mg/500 mL of diluent ‡ 1,000 mcg/mL or 250 mg/250 mL of diluent

Rates of infusion in mL/h for Dobutamine concentrations of 500 mcg/mL, 1,000 mcg/mL, and 2,000 mcg/mL are given in Table 2.

Table 2
Drug Delivery Rate (mcg/kg/min)	Dobutamine Infusion Rate (mL/h) for 500 mcg/mL concentration
	Patient Body Weight (kg)

	30	40	50	60	70	80	90	100	110
2.5	9	12	15	18	21	24	27	30	33
5	18	24	30	36	42	48	54	60	66
7.5	27	36	45	54	63	72	81	90	99
10	36	48	60	72	84	96	108	120	132
12.5	45	60	75	90	105	120	135	150	165
15	54	72	90	108	126	144	162	180	198

Drug Delivery Rate (mcg/kg/min)	Dobutamine Infusion Rate (mL/h) for 1,000 mcg/mL concentration
	Patient Body Weight (kg)

	30	40	50	60	70	80	90	100	110
2.5	4.5	6	7.5	9	10.5	12	13.5	15	16.5
5	9	12	15	18	21	24	27	30	33
7.5	13.5	18	22.5	27	31.5	36	40.5	45	49.5
10	18	24	30	36	42	48	54	60	66
12.5	22.5	30	37.5	45	52.5	60	67.5	75	82.5
15	27	36	45	54	63	72	81	90	99

Drug Delivery Rate (mcg/kg/min)	Dobutamine Infusion Rate (mL/h) for 2000 mcg/mL concentration
	Patient Body Weight (kg)

	30	40	50	60	70	80	90	100	110
2.5	2	3	4	4.5	5	6	7	7.5	8
5	4.5	6	7.5	9	10.5	12	13.5	15	16.5
7.5	7	9	11	13.5	16	18	20	22.5	25
10	9	12	15	18	21	24	27	30	33
12.5	11	15	19	22.5	26	30	34	37.5	41
15	13.5	18	22.5	27	31.5	36	40.5	45	49.5

The rate of administration and the duration of therapy should be adjusted according to the patient's response as determined by heart rate, presence of ectopic activity, blood pressure, urine flow, and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output.

Concentrations of up to 5,000 mcg/mL have been administered to humans (250 mg/50 mL). The final volume administered should be determined by the fluid requirements of the patient.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for a Pfizer medicine or a vaccine.

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.